In the study, we have used the Wilms’ tumor gene (WT1) as a biomarker to evaluate its expression in local adult patients with newly diagnosed acute leukemia, including both acute myeloid and lymphoid leukemias (AML and ALL). The gene discussed is WT1; the disease is acute lymphoblastic leukemia.